Experimental pancreatic cancer combo trial halted early
NCT ID NCT05417386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether adding the experimental drug NIS793 to standard chemotherapy (FOLFIRINOX) could help people with metastatic pancreatic cancer. Only 4 people took part before the study was stopped. The goal was to find a safe dose and see if the combination could make tumors removable by surgery. Because the study was terminated early, results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a pill rouse the immune system against pancreatic cancer?
- Can a new ultrasound technique spot hidden pancreatic cancers earlier?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can three common drugs boost chemotherapy against pancreatic cancer?
- A simple breath test might spot multiple cancers before symptoms appear